Berkshire Hathaway Has a Cash Problem Most Companies Would Love to Have

Berkshire Hathaway ended Q1 with $390.7 billion in cash, cash equivalents, and short-term Treasury bills, up 14% year over year and larger than the market caps of most companies. Warren Buffett said Berkshire remains willing to deploy capital but only for a major acquisition at a sensible price, after buying OxyChem for $9.7 billion instead. The piece is primarily a commentary on Berkshire’s liquidity and capital allocation stance rather than a new operating development.

Analysis

Berkshire’s cash mountain is less a sign of missed opportunity than a volatility buffer that lets it be a forced seller of nothing. The second-order effect is that this balance sheet can now act like a countercyclical option book: in any dislocation, Berkshire can negotiate from a position of scarcity premium, which should compress the cost of capital for anything it buys and widen the bid/ask gap for stressed sellers. That makes Berkshire itself a latent buyer of last resort, which is strategically valuable even if it is temporarily drags on ROE.

The underappreciated market implication is that Berkshire’s restraint removes one of the few remaining “price-insensitive” sources of demand in public markets and private deals. If management keeps waiting, that becomes a quiet headwind for high-quality cyclical and industrial assets because sellers lose a natural deep-pocketed anchor bid; conversely, if Berkshire finally deploys even 10% of cash, the signaling effect could re-rate the entire M&A complex and tighten credit spreads in acquisition targets. OXY is the clearest embedded beneficiary because Berkshire has shown willingness to support the asset class there, and the optionality on further adjacency purchases remains non-trivial.

The contrarian view is that the market is overfocusing on idle cash as inefficiency and underpricing the duration of that option value in an elevated valuation regime. If equity multiples stay rich for another 6-12 months, Berkshire’s patience may continue to outperform because it avoids overpaying into peak valuations; the risk is not cash drag but a prolonged inability to compound through acquisitions. The true reversal catalyst is not a cheaper stock market in abstract, but a specific forced seller event in insurance, rails, utilities, or industrials that gives Berkshire a control premium entry point at a mid-teens FCF yield.

For public holders, this is more a relative-value setup than a directional one: Berkshire should outperform in a drawdown and lag in a melt-up, so timing matters more than conviction.

Key Decisions for Investors

• Hold/accumulate BRK.B on market pullbacks over the next 3-6 months; the cash overhang is a convexity asset in a risk-off tape and should protect downside better than peers with weaker balance sheets.
• Long OXY vs. short CVX as a 3-9 month pair: OXY retains Berkshire-related strategic optionality and a more event-driven capital structure, while CVX is a cleaner beta trade with less deal asymmetry.
• Sell downside in BRK.B via 6-12 month put spreads only after a volatility spike; the thesis is that the stock should outperform in any credit/liquidity scare, making elevated implied vol a sellable premium source.
• Avoid chasing large-cap quality at current levels; instead wait for a forced-seller event before entering M&A beneficiaries, since Berkshire’s real edge is only expressed when sellers are price-sensitive and time-constrained.